Estimating prevalence of problem drug use at national level in countries of the European Union and Norway
Estimating prevalence of problem drug use at national level in countries of the European Union and Norway
复制标题
DOI：
10.1046/j.1360-0443.2003.00326.x
复制
发表时间：
2003-04-01
期刊：
影响因子：
6
通讯作者：
Wiessing, L
中科院分区：
文献类型：
--
作者：
Kraus, L;Augustin, R;Wiessing, L
Objectives本文将介绍最新的估计问题药物使用在欧洲成员国和探讨的comparability.Methods问题药物使用的估计，根据商定的准则，从所有欧盟国家和挪威收集的问题。方法包括基于治疗、警察、死亡率和艾滋病/艾滋病毒数据的乘数、捕获-再捕获法和多变量指标法。患病率估计转化为每1000人年龄在15-64 years.Results目标人群根据数据选择而变化。可以确定六种部分重叠的药物使用类型的估计数：“问题阿片剂使用”、“问题阿片剂或可卡因使用”、“问题安非他明或阿片剂使用”、“问题药物使用”、“（目前）注射”和“终生注射”。使用注射器的比率从德国的2.6到卢森堡的4.8不等;奥地利、丹麦、芬兰、葡萄牙和联合王国的比率都在这一范围内。在问题阿片剂使用方面，发现一组流行率高的国家平均发生率超过6例（意大利、卢森堡、西班牙和联合王国），一组流行率较低的国家平均发生率接近3例（奥地利、德国、爱尔兰、荷兰）。率获得法国（问题鸦片或可卡因的使用），芬兰和瑞典（问题安非他明或鸦片的使用）是不直接可比的，这些rate.Conclusions之间的跨国比较应与护理和估计的目标人群可能会有很大的不同国家之间。为估计国家一级各种形式的问题药物使用情况，建议采用多方法方法。
Objectives This paper will present the most recent estimates for problematic drug use in European Member States and explore the problems of comparability.Methods Estimates of problematic drug use, derived according to agreed guidelines, were collected from all EU countries and Norway. Methods included multipliers based on treatment, police, mortality and AIDS/HIV data, the capture-recapture method and the multivariate indicator method. Prevalence estimates were transformed into rates per 1000 population aged 15-64 years.Results Target populations varied according to data selection. Estimates for six partially overlapping types of drug use could be identified: 'problem opiate use', 'problem opiate or cocaine use','problem amphetamine or opiate use','problem drug use', '(current) injecting' and 'life-time injecting'. Rates of injectors ranged from 2.6 in Germany to 4.8 in Luxembourg; rates in Austria, Denmark, Finland, Portugal and the United Kingdom fell within this range. For problem opiate use, a group of high prevalence countries were found with average rates exceeding six cases (Italy, Luxembourg, Spain and the United Kingdom) and a group with lower prevalence with average rates close to three cases (Austria, Germany, Ireland, the Netherlands). Rates obtained for France (problem opiate or cocaine use), Finland and Sweden (problem amphetamine or opiate use) are not directly comparable and fall between these rates.Conclusions Cross-national comparisons should be made with care and estimated target populations may vary greatly between countries. For estimating various forms of problem drug use at national level, a multi-method approach is recommended.